ImpriMed ex vivo cro services
Eliminate costly drug development failures –– leverage real human biology for confident decisions
Human‑Relevant, Predictive Ex Vivo Data on xCellSense™
ImpriMed has developed a proprietary method for analyzing ex vivo drug sensitivities (DS) of anticancer drugs,
enabling direct measurement of therapeutic effects on live patient cancer cells.
⚠️ The Challenge
Traditional preclinical models fail to capture the complexity and heterogeneity of real human disease — limiting their ability to predict clinical response.
✅ The Solution: ImpriMed
ImpriMed provides human-relevant ex vivo testing on live patient samples, offering early, data-driven insight into clinical performance.
Closing the Gap in Hematologic Oncology Development
Biologics with direct cytotoxic effects
Small molecules
Peptides
Oligonucleotides
Enzymes
xCellSense™ provides a validated functional precision approach integrating:
Drug sensitivity testing
Combination synergy analysis
Advanced analytics using AI
Specialized in hematologic malignancy
Support for trial design and patient selection
xCellSense™ Functional Testing identifies patients most likely to respond, enables smarter enrollement strategies, and supports trial enrichment and precision-driven design.
AI-powered Risk Stratification for:
The Technology Behind xCellSense™
ImpriMed's Proprietary Optimum Media maintains high ex vivo viability and stability of blood cancer patients' primary cells after biopsy
Featured Publications: AML
Quantitative ex vivo synergy profiling uncovers heterogeneous combination responses in acute myeloid leukemia
Quantitative ex vivo synergy profiling uncovers heterogeneous combination responses in AML primary samples
Ex vivo drug sensitivity testing in Korean AML patients: Integration of functional and genomic profiles for predicting clinical response and survival
Also in the spotlight
Quantitative ex vivo assessment of chemotherapy synergy using patient-derived non-Hodgkin lymphoma samples
Predicting Chemotherapy Response in Patients With Advanced or Metastatic Pancreatic Cancer Using Machine Learning
ML-based sequential analysis to assist selection between VMP and RD for newly diagnosed multiple myeloma
De-risking early stage development
1
Human‑Relevant Biology
We test compounds directly on primary patientsamples, capturing the true heterogeneityof hematologic malignancies.
2
Faster, Lower‑Risk Development
Generate clinically meaningful insights in weeks 〞not months, reducing uncertaintybefore entering the clinic.
3
Better Trial Design & Patient Selection
Identify responsive patient subgroups through:
- Immunophenotyping
- Functional response profiling
- Machine learning-based prediction models
4
Differentiation in a Competitive Landscape
Strengthen IND packages, investor materials,and partnership discussionswith real-world functional data.
How we complement your programs
We help clients:
ImpriMed provides a human-relevant, predictive, and scalable ex vivo CRO service designedto accelerate development, sharpen clinical strategy, and improve the probability of clinical success.
Expanded indications
ImpriMed began receiving pancreatic cancer samples in November 2025, and both indications are currently being integrated into our service portfolio.
Pancreatic cancer
Rheumatoid Arthritis
Request a Proposal
Are you interested in receiving a proposal from ImpriMed? Leave us a message and we will get back to you shortly.
